➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Express Scripts
AstraZeneca
Colorcon

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 10,450,383

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,450,383
Title:Carbonic anhydrase IX (G250) antibodies and methods of use thereof
Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are the methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
Inventor(s): Marasco; Wayne A. (Wellesley, MA), Lo; Agnes (Jamaica Plain, MA), Xu; Chen (Beijing, CN), Zhu; Quan (Southborough, MA)
Assignee: DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA)
Application Number:15/590,678
Patent Claims:see list of patent claims

Details for Patent 10,450,383

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 001 2018-04-09   Start Trial DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) 2025-12-02 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) 2025-12-02 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) 2025-12-02 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) 2025-12-02 RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) 2025-12-02 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) 2025-12-02 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
Medtronic
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.